Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
RIGL > SEC Filings for RIGL > Form 8-K on 6-Dec-2013All Recent SEC Filings

Show all filings for RIGEL PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for RIGEL PHARMACEUTICALS INC


6-Dec-2013

Termination of a Material Definitive Agreement


Item 1.02. Termination of a Material Definitive Agreement.

On December 4, 2013, the License and Collaboration Agreement, dated February 5, 2010 (the "Agreement"), between Rigel Pharmaceuticals, Inc. (the "Company") and AstraZeneca AB ("AZ") was terminated pursuant to notice from AZ. Under the Agreement, AZ was responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of products containing the Company's oral spleen tyrosine kinase ("SYK") inhibitors. As previously disclosed, in June 2013, AZ announced the topline results from two Phase 3 clinical trials investigating fostamatinib, the first oral SYK inhibitor in development for rheumatoid arthritis ("RA"). Based on the totality of the results of the Phase 3 program in patients with RA, AZ informed the Company that it would not proceed with regulatory filings. As a result of the termination of the Agreement, all rights to fostamatinib revert to the Company.


  Add RIGL to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for RIGL - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.